The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2016 | Graft-versus-host disease (GvHD): Advances at EBMT 2016
At the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), held in Valencia, Spain, EBMT 2016 President Mohamad Mohty, MD, PhD, from Saint-Antoine Hospital, Paris, France, discusses graft-versus-host disease (GvHD), a complication that can occur after allogeneic transplantation and be a major barrier to the success of stem cell transplantation. Dr Mohty gives an overview of EBMT 2016 discussions, which address GvHD prophylaxis, pharmacologic agents and the role of polyclonal antibodies.
